Therapeutic molecules

Abstract

The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.

1 - 73 . (canceled) 
     
     
         74 . A method for treating prostate cancer or a PSMA-expressing cancer comprising administering a therapeutically-effective amount of a binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody or a pharmaceutical composition comprising a binding molecule capable of binding human PSMA comprising a single human variable heavy chain domain (VH) antibody and a pharmaceutical carrier wherein said binding molecule comprises CDR1, CDR2 and CDR3 sequences selected from:
 a CDR1 sequence comprising SEQ ID NO. 81, a CDR2 sequence comprising SEQ ID NO. 82 and a CDR3 sequence comprising SEQ ID NO. 83, or   a CDR1 sequence comprising SEQ ID NO. 85, a CDR2 sequence comprising SEQ ID NO. 86 and a CDR3 sequence comprising SEQ ID NO. 87, or   a CDR1 sequence comprising SEQ ID NO. 89, a CDR2 sequence comprising SEQ ID NO. 90 and a CDR3 sequence comprising SEQ ID NO. 91, or   a CDR1 sequence comprising SEQ ID NO. 93, a CDR2 sequence comprising SEQ ID NO. 94 and a CDR3 sequence comprising SEQ ID NO. 95, or   a CDR1 sequence comprising SEQ ID NO. 97, a CDR2 sequence comprising SEQ ID NO. 98 and a CDR3 sequence comprising SEQ ID NO. 99, or   a CDR1 sequence comprising SEQ ID NO. 101, a CDR2 sequence comprising SEQ ID NO. 102 and a CDR3 sequence comprising SEQ ID NO. 103, or   a CDR1 sequence comprising SEQ ID NO. 105, a CDR2 sequence comprising SEQ ID NO. 106 and a CDR3 sequence comprising SEQ ID NO. 107, or   a CDR1 sequence comprising SEQ ID NO. 109, a CDR2 sequence comprising SEQ ID NO. 110 and a CDR3 sequence comprising SEQ ID NO. 111, or   a CDR1 sequence comprising SEQ ID NO. 113, a CDR2 sequence comprising SEQ ID NO. 114 and a CDR3 sequence comprising SEQ ID NO. 115, or   a CDR1 sequence comprising SEQ ID NO. 1117, a CDR2 sequence comprising SEQ ID NO. 1118 and a CDR3 sequence comprising SEQ ID NO. 119, or   a CDR1 sequence comprising SEQ ID NO. 121, a CDR2 sequence comprising SEQ ID NO. 122 and a CDR3 sequence comprising SEQ ID NO. 123, or   a CDR1 sequence comprising SEQ ID NO. 125, a CDR2 sequence comprising SEQ ID NO. 126 and a CDR3 sequence comprising SEQ ID NO. 127, or   a CDR1 sequence comprising SEQ ID NO. 129, a CDR2 sequence comprising SEQ ID NO. 130 and a CDR3 sequence comprising SEQ ID NO. 131, or   a CDR1 sequence comprising SEQ ID NO. 133, a CDR2 sequence comprising SEQ ID NO. 134 and a CDR3 sequence comprising SEQ ID NO. 135, or   a CDR1 sequence comprising SEQ ID NO. 137, a CDR2 sequence comprising SEQ ID NO. 138 and a CDR3 sequence comprising SEQ ID NO. 139, or   a CDR1 sequence comprising SEQ ID NO. 141, a CDR2 sequence comprising SEQ ID NO. 142 and a CDR3 sequence comprising SEQ ID NO. 143, or   a CDR1 sequence comprising SEQ ID NO. 145, a CDR2 sequence comprising SEQ ID NO. 146 and a CDR3 sequence comprising SEQ ID NO. 147, or   a CDR1 sequence comprising SEQ ID NO. 149, a CDR2 sequence comprising SEQ ID NO. 150 and a CDR3 sequence comprising SEQ ID NO. 151, or   a CDR1 sequence comprising SEQ ID NO. 153, a CDR2 sequence comprising SEQ ID NO. 154 and a CDR3 sequence comprising SEQ ID NO. 155, or   a CDR1 sequence comprising SEQ ID NO. 157, a CDR2 sequence comprising SEQ ID NO. 158 and a CDR3 sequence comprising SEQ ID NO. 159, or   a CDR1 sequence comprising SEQ ID NO. 161, a CDR2 sequence comprising SEQ ID NO. 162 and a CDR3 sequence comprising SEQ ID NO. 163, or   a CDR1 sequence comprising SEQ ID NO. 165, a CDR2 sequence comprising SEQ ID NO. 166 and a CDR3 sequence comprising SEQ ID NO. 167, or   a CDR1 sequence comprising SEQ ID NO. 169, a CDR2 sequence comprising SEQ ID NO. 170 and a CDR3 sequence comprising SEQ ID NO. 171, or   a CDR1 sequence comprising SEQ ID NO. 173, a CDR2 sequence comprising SEQ ID NO. 174 and a CDR3 sequence comprising SEQ ID NO. 175, or   a CDR1 sequence comprising SEQ ID NO. 177, a CDR2 sequence comprising SEQ ID NO. 178 and a CDR3 sequence comprising SEQ ID NO. 179.   
     
     
         75 - 92 . (canceled) 
     
     
         93 . The method according to  claim 74 , wherein said binding molecule comprises a V H  domain comprising or consisting of SEQ ID NO. 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176 or 180. 
     
     
         94 . The method according to  claim 74 , wherein said binding molecule comprises two or more single V H  domain antibodies wherein at least one of the single V H  domain antibodies binds specifically to PSMA. 
     
     
         95 . The method according to  claim 74 , wherein said binding molecule is conjugated to a toxin, enzyme, radioisotope or other chemical moiety. 
     
     
         96 . The method according to  claim 74 , wherein said binding molecule is obtained or obtainable from a mouse that does not produce any functional endogenous light or heavy chains. 
     
     
         97 . The method according to  claim 74 , wherein said binding molecule is conjugated to a VH domain or an antibody fragment that is specific for an immunooncology target.